




Fig. 1

**FAP5-FITC PEG comparison
(FITC exposure measured by aFITC-APC)**




Fig. 2A

**FAP5-FITC PEG comparison
(Bmax on MDA-MB231-hFAP)**




Fig. 2B




Fig. 3




Fig. 4A




Fig. 4B




Fig. 5A




Fig. 5B




Fig. 5C




Fig. 5D




Fig. 5E




Fig. 5F




Fig. 6A




Fig. 6B




Fig. 6C




Fig. 7A





Fig. 7C




Fig. 7D




Fig. 8A




Fig. 8A cont.




Fig. 8A cont.




Fig. 8B

Fig. 8C




Fig. 8D




Fig. 8D cont.




Fig. 8E




Fig. 8F




Fig. 9A




Fig. 9B




Fig. 10A

**FITC exposure of FAP5-FITC vs. FAP8-FITC
by aFITC-APC Ab
(Geometric Mean)**




Fig. 10B




Fig. 11




Fig. 12A




Fig. 12A cont.




Fig. 12B




Fig. 12B cont.








Fig. 13A








Fig. 16A




Fig. 16B




Fig. 17A




Fig. 17B




Fig. 18A




Fig. 18B




Fig. 19A




Fig. 19B

Single tumor-EC17+PEG8




Fig. 19C

Single tumor-EC17+PEG15




Fig. 19D

Single tumor-EC17+PEG18




Fig. 19E

Single tumor-EC17+PEG23




Fig. 19F




Fig. 20A




Fig. 20B




Fig. 21A




Fig. 21B




Fig. 22A






Fig. 22B






Fig. 24

*Fig. 25*











Fig. 25 cont.

*Fig. 25 cont.*


*Fig. 25 cont.*

*Fig. 25 cont.*


*Fig. 25 cont.*



FAP8-PEG15-FITC
Chemical Formula: $C_{62}H_{102}F_{10}N_2O_{26}S$
Molecular Weight: 1706.32



FAP8-PEG18-FITC
Chemical Formula: $C_{68}H_{110}F_{10}N_2O_{31}S$
Molecular Weight: 1838.98



FAP8-PEG23-FITC
Chemical Formula: $C_{74}H_{118}F_{10}N_2O_{36}S$
Molecular Weight: 2003.24

Fig. 25 cont.




Fig. 26A

Single tumor Disease Control




Fig. 26B

Single tumor CAR-T only




Fig. 26C

Single tumor FAP5-PEG16-FITC




Fig. 26D

Single tumor FAP8-PEG15-FITC




Fig. 26E






Fig. 27



*Fig. 28 cont.*








Fig. 28 cont.



Compound	FITC-DUPA	FITC-PEG3-DUPA	FITC-PEG6-DUPA	FITC-PEG8-DUPA	FITC-PEG12-DUPA
Kd	5.710	5.961	15.18	19.36	45.86

Fig. 29






Fig. 32A




Fig. 32C




Fig. 32B





Fig. 32D









Fig. 34A








Fig. 35




Fig. 36A




Fig. 36B




Fig. 36C




Fig. 37A




Fig. 37B




Fig. 38




Fig. 39




Fig. 40A






Fig. 40B






Fig. 41B




Fig. 41C

TagCAR Lentiviral Particle




Fig. 42A

Fig. 42B





Fig. 42C






Fig. 42D




Fig. 43A




Fig. 43B




Fig. 43C




Fig. 44A




Fig. 44B




Fig. 45A




Fig. 45B




Fig. 45C




Fig. 45D




Fig. 46A




Fig. 46A cont.




Fig. 46B




Fig. 46B cont.




Fig. 46C




Fig. 47A




Fig. 47B




Fig. 48A





Fig. 48B

Human CAR T cell count (per 1ul blood)



h-IFN γ from mice blood




Fig. 48C





Fig. 48D



KB Tumor Growth (4M5.3 CAR-T)




Fig. 48E





Fig. 48E cont.

IHC staining from mice study (alpha
smooth muscle actin)


CAR-T only

CAR-T + FAP-FITC



CAR-T + EC17


CAR-T + EC17 + FAP-FITC



IHC staining from mice study (alpha
smooth muscle actin)

CAR-T only

CAR-T + FAP-FITC



CAR-T + EC17

CAR-T + EC17 + FAP-FITC

Fig. 48F




Fig. 48F cont.




Fig. 49A

HOS-PSMA4+ tumor growth






Fig. 49B

Human T cell counts in blood T cell counts in HOS-PSMA tumors





KB-PSMA tumor growth





Fig. 50

human T cell counts in blood (day 29)*Fig. 50 cont.*




Fig. 51A




Fig. 51B




Fig. 51C




Fig. 52A




Fig. 52B




Fig. 52C




Fig. 53A




Fig. 53B




Fig. 53C




Fig. 54A




Fig. 54B





Fig. 54C



Cancer associated fibroblast (Hs894)
killing by anti-FITC CAR T




Fig. 55B




Fig. 56A




Fig. 56B




Fig. 56C




Fig. 56D




Fig. 56E




Fig. 57A




Fig. 57B




Fig. 58A




Fig. 58B




Fig. 59




Fig. 60